We are live on ! Find out more
EYEGW

Eyegate Pharmaceuticals, Inc. Warrants
EYEGW

Delisted

EYEGW was delisted on the 5th of August, 2020.

Back to rankings

5 hedge funds and large institutions have $50K invested in Eyegate Pharmaceuticals, Inc. Warrants in 2017 Q1 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, 1 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more first-time investments, than exits

New positions opened: 1 | Existing positions closed: 1

17% less funds holding

Funds holding: 6 → 5 (-1)

58% less capital invested

Capital invested by funds: $119K → $50K (-$69K)

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 1

Holders
5
Holders Change
-1
Holders Change %
-16.67%
% of All Funds
0.12%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
–
Reduced
1
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$11.2K

Top Sellers

Rank Fund Capital Flow
1
SM
Sabby Management
Florida
-$6K
2
ICM
Ionic Capital Management
New York
-$4.35K

EYEGW Hedge Fund Activity: Q1 2017 in Review

5 of the 4,034 institutional investors tracked by Wall St. Rank reported a position in Eyegate Pharmaceuticals, Inc. Warrants (EYEGW) for Q1 2017, worth a combined $50K — down 58% from $119K a quarter earlier.

Fund positioning in EYEGW was balanced in Q1 2017: 1 fund opened new positions, 1 closed out, 0 added to existing stakes and 1 trimmed.

The largest buyer was BlackRock, opening a new position worth an estimated $11.2K. The largest seller was Sabby Management, exiting entirely with an estimated $6K sold.

  • 5 institutional investors held Eyegate Pharmaceuticals, Inc. Warrants (EYEGW) as of Q1 2017, down from 6 in Q4 2016.
  • Funds reported $50K of Eyegate Pharmaceuticals, Inc. Warrants stock for Q1 2017, down 58% quarter-over-quarter.
  • 1 fund opened new Eyegate Pharmaceuticals, Inc. Warrants positions in Q1 2017 and 1 closed out, a net change of 0 holders.
  • The largest Eyegate Pharmaceuticals, Inc. Warrants buyer in Q1 2017 was BlackRock, an estimated $11.2K added.
  • The largest Eyegate Pharmaceuticals, Inc. Warrants seller in Q1 2017 was Sabby Management, an estimated $6K sold.

Based on aggregated 13F filings for Q1 2017.